Conferences
ESMO 2023: Discussant - MEDI5752 (Volrustomig) for 1st Line Advanced Clear Cell Renal Cell Carcinoma & TIDE-A
October 23, 2023
ESMO 2023: TIDE-A: Phase II Study of Avelumab plus Intermittent Axitinib in Previously Untreated Patients with mRCC
October 23, 2023
ESMO 2023: SunRISe-1: TAR-200 Monotherapy in Patients With BCG Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer (HR NMIBC)
October 23, 2023
ESMO 2023: Treatment Patterns Among Novel Hormonal Therapy-experienced Patients with mCRPC
October 23, 2023
ESMO 2023: Exposure-Safety Analyses of Talazoparib in Combination of Enzalutamide in Patients with mCRPC in TALAPRO-2 Trial
October 23, 2023
ESMO 2023: 177Lu-PSMA-617 in Pre- and Post-Taxane mCRPC Setting: Results from the Phase II IRST-185.03 Clinical Trial
October 23, 2023
ESMO 2023: PSMA-Alpha Targeted Radionuclide Therapy with or without Prior PSMA-Beta Targeted Radionuclide Therapy
October 22, 2023
ESMO 2023: ABACUS-2, A Phase II Study Investigating the Safety and Efficacy of Neoadjuvant Atezolizumab in Non-Urothelial Muscle Invasive Bladder Cancer
October 22, 2023
ESMO 2023: Discussant: EV-302/KEYNOTE-A39 & CheckMate 901: Welcoming a New Standard of Care in the First-Line Treatment of Urothelial Carcinoma
October 22, 2023
ESMO 2023: Invited Discussant – PET-MUSE and the Phase 3 THOR Study
October 22, 2023